Tag Archives: PGNX

Hot Heal Care Stocks To Invest In 2018

The dollar advanced against all other major currencies on Friday, as traders waited for the closely watched U.S. jobs report that could help steer the future of Federal Reserve rate hikes.

What are currencies doing?

The ICE U.S. Dollar Index
DXY, +0.19%
climbed 0.2% to 92.041, trimming its weekly loss to 0.1%.

Hot Heal Care Stocks To Invest In 2018: Marathon Petroleum Corporation(MPC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Marathon Petroleum Corporation (MPC) is an American petroleum refining, marketing, and transportation company headquartered in Findlay, Ohio, explains dividend reinvestment expert Vita Nelson, editor of DirectInvesting.

  • [By Stephen Mack]

    We’ve seen this happen before. In December, shares of Russian oil company Rosneft jumped 21% in two weeks when it was acquired by Glencore Plc. (LON: GLEN). And back in 2015, MarkWest Energy Partners LP (NYSE: MWE) enjoyed a similar jump when it was acquired by Marathon Petroleum Corp (NYSE: MPC).

Hot Heal Care Stocks To Invest In 2018: Old National Bancorp Capital Trust I(ONB)

Advisors’ Opinion:

  • [By kiplinger]

     Old National Bancorp (ONB) is a 181-year-old financial institution with 195 branches, mainly in the Midwest. The stock, which is still down by about one-third from its prerecession high, trades at just 13 times projected 2016 earnings and yields an attractive 3.4%. If interest rates ever rise, the bank should benefit from a widening spread between its cost of funds and the interest rates borrowers pay.

    It’s a favorite of David Dreman, author of the classic 1980 book Contrarian Investment Strategy. His philosophy: “We believe that the markets are not perfectly efficient.” Some stocks, in other words, are judged by the market to be cheaper than their actual worth.
  • [By Ben Levisohn]

    The twenty stocks in Worth’s basket are: Ameriprise Financial (AMP) Bank of America, Banner (BANR), Citigroup, Citizens Financial Group (CFG), East West Bancorp (EWBC), First NBC Bank Holding (FNBC), HFF (HF), KeyCorp(KEY), Legacy Texas Financial Group (LTXB), Lincoln National (LNC), Morgan Stanley, Old National Bancorp (ONB), PacWest Bancorp (PACW), PNC Financial Services Group (PNC), Principal Financial Group (PFG), Stifel Financial (SF), SVB Financial Group (SIVB), TCF Financial (TCB), and Wells Fargo.

Hot Heal Care Stocks To Invest In 2018: Voyager Therapeutics, Inc.(VYGR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Voyager Therapeutics Inc (NASDAQ: VYGR) got a boost, shooting up 20 percent to $13.10 after the company announced 'positive' results from ongoing Phase 1b trial of VY-AADC01 for advanced Parkinson's disease.

Hot Heal Care Stocks To Invest In 2018: Investment Technology Group, Inc.(ITG)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Investment Technology Group Inc. (NYSE: ITG) was downgraded to Market Perform from outperform by KeefeBruyette & Woods.

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

Hot Heal Care Stocks To Invest In 2018: MGE Energy Inc.(MGEE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, utilities shares fell by 0.75 percent. Meanwhile, top losers in the sector included California Water Service Group (NYSE: CWT), down 7 percent, and MGE Energy, Inc. (NASDAQ: MGEE), down 6 percent.

Hot Heal Care Stocks To Invest In 2018: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

Top Casino Stocks To Watch For 2018

Michael E. Lewitt

Back in April, I recommendedCaesars Entertainment Corp.(Nasdaq: CZR) as a buy – but warned you that this was a play that might take some time to mature.

If you haven’t gotten in already, you’ll want to do it soon.

After months of bitter wrangling, the much-beleaguered Caesars has finally reached a $5 billion deal with the private-equity sponsors that looted the company,Apollo Global Management, LLC(NYSE: APO) andTPG Capital(formerly Texas Pacific Group). Pending approval by the U.S. Bankruptcy Court in Chicago, CZR is now set to leave bankruptcy, get rid of its debt, and get back on its feet.

Of course, this means very good news for stockholders (like you, I hope).

Here’s why you can expect to start seeing profits…

CZR’s Bonds Are Recovering – and Its Stock Will, Too

The sad chapter of Caesars Entertainment’s ownership by these two private-equity firms appears to be mercifully coming to an end.The firms agreed to increase their offer to repay the creditors some (but not all) of the billions of dollars they looted from the company in a desperate and disgusting effort to save their ill-fated investment in the casino giant. While they will retain an equity interest in the company, a majority of the stock will be held by the creditors who suffered at their hands.

Top Casino Stocks To Watch For 2018: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

Top Casino Stocks To Watch For 2018: Cimpress N.V(CMPR)

Advisors’ Opinion:

  • [By Steve Symington]

    Shares ofCimpress NV(NASDAQ:CMPR)climbed 14.6% in 2016,according to data from S&P Global Market Intelligence, as the mass customization specialist steadfastly pursued its novel long-term efforts to generate shareholder value.

Top Casino Stocks To Watch For 2018: PPL Corporation(PPL)

Advisors’ Opinion:

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.81 after closing Friday at $31.13. The 52-week high is $40.20. Volume was about 3.5 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $32.48 after closing Monday at $33.97. The 52-week high is $40.20. Volume was about 5.9 million, nearly a third higher than the daily average of around 3.9 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.53 after closing Tuesday at $32.42. The 52-week high is $40.20. Volume was about 15.5 million, more than three times the daily average of around 4 million shares. The electric utility company took a downgrade on Tuesday and the fallout continues to drop.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.74 after closing Tuesday at $30.76. The 52-week high is $40.20. Volume was about 3.2 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.11 after closing Wednesday at $31.59. The 52-week high is $40.20. Volume was about 9.6 million, more than double the daily average of around 4.2 million shares. The electric utility company had no specific news.

Hot Stocks To Watch For 2018

GoPro: A Few Quick Points

Once upon a time GoPro (GPRO) was an up and coming investor favorite, being pushed to radical valuations most stocks can only dream of. However, after some bad quarters and some poor business decisions, this once-upon-a-time investor favorite has dropped from highs of nearly $87 a share to a measly $8.70 as of recent close.

Hot Stocks To Watch For 2018: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

Hot Stocks To Watch For 2018: Petroleum Resources Corporation(PEO)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, financial shares fell 0.13 percent. Meanwhile, top losers in the sector included Adams Natural Resources Fund Inc (NYSE: PEO), down 4 percent, and Old Point Financial Corporation (NASDAQ: OPOF) down 3 percent.

Hot Stocks To Watch For 2018: Oshkosh Corporation(OSK)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Oshkosh (OSK) was downgraded to neutral from buy at Bank of America/Merrill Lynch. $62 price target. The valuation is less attractive, as the stock is trading at 21x expected 2017 earnings, analysts said. 

  • [By Shanthi Rexaline]

    The six companies that met the criterion are:

    Oshkosh Corp (NYSE: OSK). Phillips 66 (NYSE: PSX). SpartanNash Co (NASDAQ: SPTN). Suncor Energy Inc. (USA) (NYSE: SU). Washington Federal Inc. (NASDAQ: WAFD). Barnes & Noble, Inc. (NYSE: BKS).
    Oshkosh

    Oshkosh is a manufacturer of specialty vehicles and vehicle bodies and is based in Wisconsin. The company operates under four business segments, namely access equipment, defense, fire and emergency, and commercial.

  • [By Rich Smith]

      I first named Oshkosh my top stock pick back in September, when the stock cost $42 and change. Since then, the stock has gone down, and sells for $3 less. So am I supposed to dislike Oshkosh stock now?

    No. To the contrary, I like it even more. (About $3 more, in fact).

    You see, even in the process of picking Oshkosh back then, I warned investors: "I don’t know whether Oshkosh will be the best-performing stock in the world in the month of September, but I’ve got a strong hunch about the next six months." And that hunch remains — because the facts have not changed.

    This past summer, Oshkosh was named the winner of the Pentagon’s contract to build a next-gen "Humvee" — an armored Joint Light Tactical Vehicle that will serve the U.S. military for decades to come. Oshkosh won an initial award to produce 17,000 vehicles for $6.7 billion. Ultimately, though, this is a contract that could swell to $30 billion or more for production, maintenance, and upgrade of approximately 55,000 JLTVs across all military branches.

    So why hasn’t Oshkosh stock moved in response to the contract? Mainly because rival bidderLockheed Martin threw a monkey wrench into the contracts process, first protesting the JLTV award to Oshkosh, and then, when that protest was rejected, filing suit in court to try to win the contract away from its rival.

    Personally, I think Lockheed Martin will lose that suit as well. After all, Lockheed’s forte is in fighter jets, while Oshkosh is the military’s premier supplier of trucks like JLTV, as well as the Army’s M-ATV vehicle (a small, all-terrain MRAP). Perhaps recognizing this, AM General, the other company that bid against Oshkosh on JLTV and lost, declined to protest the award. Lockheed took the other road, but I expect it will be a dead end for Lockheed as well.

Hot Stocks To Watch For 2018: Minerva Neurosciences, Inc(NERV)

Advisors’ Opinion:

  • [By Lisa Levin]

    Minerva Neurosciences Inc (NASDAQ: NERV) shares shot up 194 percent to $10.39 after the company revealed positive top line results from a prospective Phase IIb, 12-week, randomized, double-blind, placebo-controlled parallel clinical study evaluating the efficacy, safety and tolerability of MIN-101 in patients with negative symptoms of schizophrenia.

Hot Stocks To Watch For 2018: MarketAxess Holdings, Inc.(MKTX)

Advisors’ Opinion:

  • [By ]

    This is why I’m bullish on a company that promises to mitigate the liquidity issues facing the bond market. The company is MarketAxess (Nasdaq: MKTX).

  • [By Joe Tenebruso]

    MarketAxessHoldings (NASDAQ:MKTX)reported first-quarter results on April 26. The electronic trading platform is enjoying strong gains in revenue and profits as it continues to take share of the massive global fixed-income market.

best stock under 10

Shares of Scynexis (NASDAQ:SCYX) are down over 40% in the past year, although it appears the bottom might be in around the $3 mark.

SCYX data by YCharts

The company is focused on developing lead asset SCY-078, a triterpene glucan synthase inhibitor that is the first of a new class of anti-fungal treatments. It has the added convenience of being administered by IV or orally and a strong safety profile, as it is not associated with renal and CNS toxicities, as well as holds a low risk for drug on drug interactions. SCY-078 targets synthesis of 尾-(1,3)-glucan in the fungal cell wall (absent in humans), and thus are are limited off-target effects and no cross-resistance with Azoles.

best stock under 10: Huntington Bancshares Incorporated(HBAN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Who is at the lower-end of the range for 2016 payout ratios? We expect Zions Bancorporation, Huntington Bancshares (HBAN), andBank of America to seek the least amount of capital return in 2016 (ranging between 50-60% of estimated earnings).

best stock under 10: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

best stock under 10: Aon Corporation(AON)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    We’re seeing the exact same price pattern playing out in shares of $29 billion risk and insurance consultancy firm Aon plc (AON) . Aon has been a strong performer for all of 2016, up 20% since the calendar flipped to January. But don’t worry if you’ve missed the move – an ascending triangle pattern is signaling a second leg higher here. For Aon, the breakout level to watch is resistance up at $113.

best stock under 10: Stage Stores, Inc.(SSI)

Advisors’ Opinion:

  • [By Paul Ausick]

    Stage Stores Inc. (NYSE: SSI) dropped nearly 20% on Monday to post a new 52-week low of $3.21 after closing at $4.00 on Friday. Volume was more than 5 times the daily average of about 650,000 shares. The company posted poor holiday season sales last Friday and lowered its guidance.

  • [By Lisa Levin]

    Stage Stores Inc (NYSE: SSI) was down, falling around 16 percent to $3.35 as the company reported a drop in its holiday season same-store sales and lowered its earnings guidance. The retailer’s same-store sales dropped 7.3 percent for the nine-week period ending December 31, 2016.

best stock under 10: AxoGen, Inc.(AXGN)

Advisors’ Opinion:

  • [By Lisa Levin]

    AxoGen, Inc. (NASDAQ: AXGN) was down, falling around 10 percent to $22.42. AxoGen reported a proposed public offering of common stock.

    Commodities

best stock under 10: EQT Midstream Partners, LP(EQM)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Not only does Jana consider the deal price overvalued, but it looks to redirect EQT’s focus to a breakup of pipeline operations to transform the core company into an exploration & production firm. The pipelines already trade publicly under EQT Midstream Partners LP (NYSE: EQM) and EQT GP Holdings LP (NYSE: EQGP).

  • [By WWW.INVESTOPEDIA.COM]

    Companies in the oil storage business can take advantage of what is known as contango, which is when forward prices are higher than current prices, allowing the purchase of cheap oil to be stored and sold at a later date while securing income using derivatives. Five companies that appear to be in a good position to take advantage of reduced oil storage capacity are Magellan Midstream Partners (NYSE: MMP), Enterprise Products Partners (NYSE: EDP), Spectra Energy Partners (NYSE: SEP), Buckeye Partners (NYSE: BPL) and EQT Midstream Partners (NYSE: EQM).

nyse trading hours

Ford Motor Company and My Position

I have been invested in Ford Motor Company (NYSE:F) for some time now. I made my fist small investment in F three years ago, and mostly over the last two years I have increased my holding. As can be seen from previous articles I have written, I have been a bull of the company. At the current time I do not consider the stock a buy based upon an appreciation in the stock price, but I do think the stock is a good investment for the dividend. Ford trades at a very low PE ratio of 5.86, and I consider the stock to be low0risk at the current levels, which I will explain later on. The company offers a yield of close to 5%, and that is excluding the special dividend. I have included in the article more on the dividend and special dividend and how Ford has prudently chosen to compensate shareholders.

My Position

Unfortunately I have not always been correct on my bullish thesis. Being wrong has cost me some money over the last couple of years. The first area that hurt my bull thesis is the slow growth that the company has experienced in China. I expected the growth and profitability of the Chinese market to be much better that it has been for Ford. While there has been growth in China, it was not nearly as strong or as profitable as I anticipated. I also thought that the dividend payment would support the stock price from dropping to the levels that it has. There are a lot of yield-hungry investors, and I thought the price of the stock would be supported around the 4% yield range, which would put the stock price at $15 a share (not including the special dividend). Instead the yield currently sits at 4.9%.

nyse trading hours: First Commonwealth Financial Corporation(FCF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The last year Netflix generated positive free cash flow (FCF), was 2010, which happens to coincide with the year it began significantly increasing its content library, per Figure 2 above. Since then, Netflix has burned through cumulative $3.6 billion in cash, per Figure 3, and the cash burn is only accelerating. In 2015, NFLX’s FCF sat at -$1.6 billion, and over the last twelve months, FCF has worsened to -$1.9 billion.

nyse trading hours: KongZhong Corporation(KZ)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

nyse trading hours: Aerohive Networks, Inc.(HIVE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Aerohive Networks Inc (NYSE: HIVE) were down 33 percent to $3.10. Aerohive Networks reported a Q2 loss of $3.9 million on revenue of $42.3 million, and disclosed that it has extended its $10 million buyback plan.

  • [By Monica Gerson]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.16 per share on revenue of $17.34 billion before the opening bell. Citigroup shares rose 0.47 percent to $48.70 in after-hours trading.
    HP Inc (NYSE: HPQ) disclosed that it would be implementing a restructuring plan that would likely result in the firing of 3,000 to 4,000 employees, annual savings of $200 million to $300 million, and a charge of $350 million to $500 million. Management also announced a 7 percent surge in the stock’s dividend and an additional $3 million share repurchase program. The company issued its outlook for fiscal 2017, guiding for EPS of $1.55 to $1.65, mostly below the Street’s consensus of $1.64. HP shares fell 1.32 percent to $14.95 in the after-hours trading session.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.39 per share on revenue of $23.99 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.37 perecent to $67.99 in after-hours trading.
    Aerohive Networks Inc (NYSE: HIVE) reported weak preliminary results for its third quarter. The company said it expects a net loss of $(0.06) to $(0.07) per share, versus consensus at $(0.04) per share. Revenue guidance of $40 million also fell short of expectations for almost $48 million. Aerohive shares dropped 18.29 percent to $4.60 in the after-hours trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

nyse trading hours: Fogo de Chao, Inc.(FOGO)

Advisors’ Opinion:

  • [By Monica Gerson]

    Fogo De Chao Inc (NASDAQ: FOGO) is expected to post its quarterly earnings at $0.28 per share on revenue of $76.80 million.

    Constellium NV (NYSE: CSTM) is estimated to report its quarterly earnings at $0.06 per share on revenue of $1.18 billion.

nyse trading hours: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

great stocks to invest in

Gilead Sciences (NSDQ:GILD)has been dedicating large capital for Research and Development(R&D) in the last few years. In fact, its R&D expenses for the trailing twelve months of $4,647 million have been the highest among all biotechnology companies, as shown in the table below. However, currently, Gilead is changing its research and development focus from hepatitis C drugs to other areas. Here’s why the developments in this space may drive Gilead’s profits and stock higher.

Source: Portfolio123

After achieving excellent resultsin thetreatment of patients across all six HCV genotypes by introducing Epclusa, and continuing to lead the HCV drugs market, Gilead seeks new revolutionary drugs for diseases that do not have a cure until now. Achieving such drugs will increase the company’s revenue and profits making it a high growth company again.

great stocks to invest in: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

great stocks to invest in: Rave Restaurant Group, Inc.(RAVE)

Advisors’ Opinion:

  • [By Rick Rouse]

    Rouse is sticking with his Best Stocks entry for this year’s competition. His selection is Rave Restaurant Group (RAVE), which owns Pie Five Pizza, a fast-casual pizza joint that Rouse thinks is changing the industry with its unique ovens.

    Says Rouse: “The company is on track to open 500 Pie Five locations over the next few years, and we are still in the early innings of this ballgame.” 

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    Rave Restaurant Group Inc (NASDAQ: RAVE) was down, falling around 18 percent to $1.65. RAVE Restaurant reported a $5 million equity rights offering.

great stocks to invest in: Compass Minerals Intl Inc(CMP)

Advisors’ Opinion:

  • [By Monica Gerson]

    Compass Minerals International, Inc. (NYSE: CMP) is projected to post its quarterly earnings at $1.33 per share on revenue of $347.03 million.

    MKS Instruments, Inc. (NASDAQ: MKSI) is estimated to post its quarterly earnings at $0.33 per share on revenue of $177.19 million.

great stocks to invest in: Actuant Corporation(ATU)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.

  • [By Monica Gerson]

    Actuant Corporation (NYSE: ATU) is estimated to report its quarterly earnings at $0.18 per share on revenue of $267.64 million.

    Jabil Circuit, Inc. (NYSE: JBL) is projected to post its quarterly earnings at $0.60 per share on revenue of $4.50 billion.

  • [By Monica Gerson]

    Actuant Corporation (NYSE: ATU) is projected to report its quarterly earnings at $0.18 per share on revenue of $267.64 million. Actuant shares dropped 3.73 percent to close at $22.98 yesterday.

great stocks to invest in: MarketAxess Holdings, Inc.(MKTX)

Advisors’ Opinion:

  • [By ]

    This is why I’m bullish on a company that promises to mitigate the liquidity issues facing the bond market. The company is MarketAxess (Nasdaq: MKTX).

  • [By Joe Tenebruso]

    MarketAxessHoldings (NASDAQ:MKTX)reported first-quarter results on April 26. The electronic trading platform is enjoying strong gains in revenue and profits as it continues to take share of the massive global fixed-income market.

Top Warren Buffett Stocks To Buy Right Now

Warren Buffett’s Berkshire Hathaway Energy – a portfolio worth $85 billion that includes renewable energy companies – just made a huge bet on “Big Data.”

In March, BHE announced that two of its subsidiary companies (though not parent company BHE itself) would partner with the young Chicago-based software startup Uptake Technologies to track their wind turbines.

In fact, the startup is so new that Buffett’s Berkshire Hathaway is Uptake’s very first publicly announced customer.

So what does Buffett see in this little-known “unicorn” startup? And more importantly, how could you profit from the same technology? Let’s take a look…

Top Warren Buffett Stocks To Buy Right Now: Medidata Solutions, Inc.(MDSO)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Wednesday, technology shares climbed by 0.94 percent. Top gainers in the sector included Marvell Technology Group Ltd. (NASDAQ: MRVL) and Medidata Solutions Inc (NASDAQ: MDSO).

  • [By Peter Graham]

    A long term performance chart shows shares of Veeva Systems outperformingunderperforming small cap peerModel N Inc (NYSE: MODN) while mid cap Medidata Solutions (NASDAQ: MDSO) has been a huge outperformer that has just moved past its 2014 peak:

Top Warren Buffett Stocks To Buy Right Now: Ollie's Bargain Outlet Holdings, Inc.(OLLI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Ollie’s Bargain Outlet Holdings Inc (NASDAQ: OLLI) is estimated to post its quarterly earnings at $0.17 per share on revenue of $190.44 million.

    MGC Diagnostics Corp (NASDAQ: MGCD) is projected to post earnings for the latest quarter.

  • [By WWW.THESTREET.COM]

    All is not lost for retail, however. Cramer continued to recommend the closeout and discount chains like TJX Stores (TJX) , Ollie’s Bargain Outlet (OLLI) and Burlington Stores (BURL) . He was also bullish on those who cater to the millennials, like Six Flags (SIX) , Dave & Busters (PLAY) and Foot Locker (FL) , where trying on shoes never seems to go out of style.

Top Warren Buffett Stocks To Buy Right Now: Ethan Allen Interiors Inc.(ETH)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wednesday was a strong day for the stock market, as the Dow finished up nearly 100 points and the S&P 500 and Nasdaq both posted gains as well. Investors remained generally upbeat about the prospects for the U.S. economy in 2017, and a rise in crude oil prices helped lift the energy sector higher during the market session. Yet comments during a press conference from President-elect Donald Trump weighed on the healthcare sector, and some individual stocks took particularly hard hits. Among the worst performers were Perrigo (NYSE:PRGO), Novadaq Technologies (NASDAQ:NVDQ), and Ethan Allen Interiors (NYSE:ETH). Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top Warren Buffett Stocks To Buy Right Now: National Grid Transco, PLC(NGG)

Advisors’ Opinion:

  • [By Travis Hoium]

    National Grid (NYSE:NGG) came out with some interesting information last week, saying 2.4 GW of distributed solar was added in the U.K. between February 2016 and February 2017 and another 1.5 GW is expected in the next year. The U.K. isn’t exactly a hotbed for solar activity, but it’s growing as an important market.

  • [By Lisa Levin]

    Tuesday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from National Grid plc (ADR) (NYSE: NGG) and Dominion Resources, Inc. (NYSE: D).

  • [By WWW.MONEYSHOW.COM]

    Among utilities, National Grid (NGG) is my best pick for 2017, as it’s an almost perfect hedge against uncertainty. It’s insulated from changes in government interest rates. It can be both an inflation hedge and a play on a strong dollar.

  • [By Tyler Crowe, Dan Caplinger, and Neha Chamaria]

    We asked three of our contributors to highlight a stock they see as a dividend stock to buy in February. They responded with automaker Ford Motors (NYSE:F), oil and gas logistics company Enterprise Products Partners (NYSE:EPD), and electricity transmission specialist National Grid (NYSE:NGG). Here’s a quick run-down as to why investors should take a look at these high-yield stocks.

Top Warren Buffett Stocks To Buy Right Now: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

what is an investment

Ridgewood, NJ, based Investment company Advisors Capital Management, LLC buys Aircastle, Alphabet, Gaming and Leisure Properties, Agilent Technologies, AECOM, Anheuser-Busch InBev SA/NV, Allergan PLC, NVR, Ciena, Quest Diagnostics, sells Kinder Morgan, Blackstone Mortgage Trust, Ares Capital, AT&T, Six Flags Entertainment during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Advisors Capital Management, LLC. As of 2017-03-31, Advisors Capital Management, LLC owns 175 stocks with a total value of $1.2 billion. These are the details of the buys and sells.

New Purchases: AYR, GOOG, GLPI, A, ACM, BUD, AGN, CIEN, DGX, AR, Added Positions: NVR, Reduced Positions: KMIPRA, BXMT, ARCC, T, SIX, CY, MIC, IBM, GM, MO, Sold Out: MSFT, TREX, SWNC, EFA, PEG, SWN,

For the details of Advisors Capital Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Advisors+Capital+Management%2C+LLC

These are the top 5 holdings of Advisors Capital Management, LLCKinder Morgan Inc (KMIPRA) – 27,070 shares, 2.33% of the total portfolio. Shares reduced by 94.85%Blackstone Mortgage Trust Inc (BXMT) – 26,166 shares, 2.25% of the total portfolio. Shares reduced by 96.84%Broadcom Ltd (AVGO) – 24,851 shares, 2.14% of the total portfolio. Shares reduced by 78.4%Qualcomm Inc (QCOM) – 24,706 shares, 2.13% of the total portfolio. Shares reduced by 91.4%Ares Capital Corp (ARCC) – 24,487 shares, 2.11% of the total portfolio. Shares reduced by 98.18%New Purchase: Aircastle Ltd (AYR)

Advisors Capital Management, LLC initiated holdings in Aircastle Ltd. The purchase prices were between $21.11 and $25.65, with an estimated average price of $23.15. The stock is now traded at around $23.56. The impact to the portfolio due to this purchase was 1.72%. The holdings were 19,983 shares as of 2017-03-31.

what is an investment: Farmer Brothers Company(FARM)

Advisors’ Opinion:

  • [By Matt Hogan]

    Finbox.io fair value data (as of January 4) shows that there are only five US manufacturing stocks that have 25% or more margin of safety: Vera Bradley, Inc. (NASDAQ: VRA), Cooper Tire & Rubber Co (NYSE: CTB), Farmer Brothers Co. (NASDAQ: FARM), Allergan plc Ordinary Shares (NYSE: AGN) and Motorcar Parts of America, Inc. (NASDAQ: MPAA).

what is an investment: Nomura Holdings Inc ADR(NMR)

Advisors’ Opinion:

  • [By Maureen Farrell]

    Shortly after Lehman declared bankruptcy, Barclays (BCS) paid $1.3 billion for most of the firm’s North American operations, its Times Square headquarters, and about 9,000 employees. Nomura Holdings (NMR) paid roughly $200 million for Lehman’s operations in Asia.

what is an investment: Clarke(t)

Advisors’ Opinion:

  • [By Stark Merrifield]

    Verizon Communications Inc. (NYSE: VZ) and AT&T Inc. (NYSE: T), as well as any other company that provides Internet or mobile phone services in the United States, would be alongside Comcast in the spy game. Each will be greenlighted to track, gather, use, and sell your data to third-party companies.

  • [By Laurie Kulikowski]

    AT&T shares currently yield a 5.6% dividend, which we believe is sustainable and will look even more solid as the company’s free cash flow grows going forward and payout ratio comes down. We expect that AT&T will report a 7.3% EPS CAGR over the next three years (’15-’18) driven by DTV synergies and organic cost cutting. This compares to Verizon’s 5.0% dividend and expected 2.5% EPS CAGR over the similar time frame, so we believe investors win with AT&T through both faster EPS growth and potential multiple expansion/dividend convergence. 

  • [By Jim Robertson]

    DirecTV is a direct broadcast satellite service provider and is a subsidiary of AT&T Inc (NYSE: T). Its satellite service, launched on June 17, 1994, transmits digital satellite television and audio to households in the United States, Latin America and the Caribbean withprimary competitorsbeing Dish Network and cable television providers. On July 24, 2015, after receiving approval from the FCC and United States Department of Justice, AT&T acquired DirecTV in a transaction valued at $48.5 billion. DirecTV would be paying$1.5 billion a year for the NFL Sunday Ticket.AT&T’s shares may have broken out of a downtrend:

what is an investment: Progenics Pharmaceuticals Inc.(PGNX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    After meeting with the senior management team of Progenics (PGNX) , Valeant’s partner for oral Relistor, we continue to think that this drug would be a good addition to Valeant’s GI (gastrointestinal) franchise. The PDUFA date for oral Relistor is 7/19/16. AlthoughValeant is leading interactions with the FDA, Progenics is highly confident regarding an approval in July based on its discussions with Valeant. Progenics believes that oral Relistor could be a $1B+ opportunity for Valeant, even with the recent decrease in opioid usage. For context, we estimate ’16 sales of $9.9B for Valeant. An approval for oral Relistor would also help remind the Street that Valeant’s brand drug pipeline is underappreciated, in our view. We think pipeline advancements for brand drugs could drive multiple expansion forValeant shares (on P/E).

  • [By Lisa Levin]

    Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares shot up 29 percent to $6.37 after announcing the FDA approval of RELISTOR tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.

what is an investment: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

what is an investment: AVEO Pharmaceuticals, Inc.(AVEO)

Advisors’ Opinion:

  • [By Lisa Levin]

    AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares shot up 69 percent to $1.23 after the company reported positive CHMP opinion for tivozanib for the treatment of advanced renal cell carcinoma.

  • [By Money Morning News Team]

    Hot penny stockscan bring investors double-digit returns in a short amount of time. For instance, AVEO Pharmaceuticals Inc. (Nasdaq: AVEO) surged 332%, from $0.73 to $3.15, from June 22 to July 10. That means any investor who bought in on June 22 more than quadrupled their initial investment in less than three weeks.